Search
Home
News
Fortune 500
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Great Place To Work
Tech
AI
Innovation
Cybersecurity
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Analytics
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Home
News
Fortune 500
Fortune 500
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Great Place To Work
Tech
Tech
AI
Innovation
Cybersecurity
Finance
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Asia
Europe
Analytics
home
home
Eli Lilly
Eli Lilly
Page 3 of 7
Newsletters
Eli Lilly’s new CFO is a 23-year company veteran—showing how pharma firms rely on a ‘deep bench of qualified talent’
By
Sheryl Estrada
September 10, 2024
Newsletters
In this year’s Global 500 list: Energy woes, retail gains, and boom times for AI and weight-loss drugs
By
Lydia Belanger
August 5, 2024
Magazine
How Eli Lilly went from pharmaceutical slowpoke to $791 billion juggernaut
By
Erika Fry
August 2, 2024
Finance
Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss
By
Prarthana Prakash
July 29, 2024
Health
Pharma giant Pfizer is trying to cash in on the weight loss drug craze with a new pill that could be a welcome needle-free alternative to pesky GLP-1 shots
By
Damian Garde
and
Bloomberg
July 11, 2024
Features
Ozempic and Wegovy are marketed as a short-term holy grail for weight loss by some startups. Doctors disagree
By
Jessica Mathews
and
Alena Botros
July 9, 2024
Commentary
Alzheimer’s made my mom unable to recognize her grandkids. Breakthroughs too late for her can change the disease’s trajectory—if diagnosis and treatment start early
By
Anne E. White
July 2, 2024
Health
Fake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs
By
Amanda Loudin
June 28, 2024
Health
Alzheimer’s drug from Eli Lilly that can slow brain-robbing disease backed by FDA advisers
By
Matthew Perrone
and
The Associated Press
June 11, 2024
Retail
Nestlé’s new foods are getting Ozempified, with slashed portions priced specifically for those on weight-loss drugs
By
Sasha Rogelberg
May 21, 2024
Retail
Denmark’s Novo Nordisk forecasts 27% sales surge but faces price pressure amid Eli Lilly competition
By
Naomi Kresge
and
Bloomberg
May 2, 2024
Health
FDA will take a deeper look into the safety and effectiveness of Lilly experimental Alzheimer’s drug
By
Tom Murphy
,
Matthew Perrone
and
The Associated Press
March 8, 2024
Lifestyle
Novo Nordisk eclipses Tesla on positive trial results for a weight loss drug that may be more powerful than its own Wegovy
By
Prarthana Prakash
March 8, 2024
Health
A billion people worldwide are obese and Ozempic and other weight-loss drugs aren’t a solution, WHO says
By
Naomi Kresge
,
Angela Feliciano
and
Bloomberg
March 1, 2024
Health
Minnesotans can buy insulin for just $35 a month over the next 5 years under a state settlement with Eli Lilly
By
Steve Karnowski
and
The Associated Press
February 8, 2024
Most Popular
AI
Russia's first AI-powered robot walked on stage to triumphant music, took a few steps, and then immediately faceplanted
By
Dave Smith
Real Estate
This 38-year-old used to be homeless and now pays $19 per month for an apartment over an LA subway station thanks to...
By
Michael Casey
and
The Associated Press
Success
Ex-Meta exec says Mark Zuckerberg taught him a lesson in work-life balance: Now he has strict rules for meetings and...
By
Orianna Rosa Royle